Alimera Sciences, Inc. (ALIM) Given “Buy” Rating at HC Wainwright
Alimera Sciences, Inc. (NASDAQ:ALIM)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Wednesday. They presently have a $5.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 257.14% from the stock’s current price.
ALIM has been the subject of several other reports. Cowen and Company set a $3.00 price objective on Alimera Sciences and gave the company a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research downgraded Alimera Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, ValuEngine downgraded Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) opened at 1.39 on Wednesday. The stock has a 50 day moving average price of $1.46 and a 200-day moving average price of $1.42. Alimera Sciences has a 52 week low of $1.03 and a 52 week high of $1.72. The firm’s market capitalization is $95.98 million.
Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $10.20 million. During the same period in the previous year, the business earned ($0.17) earnings per share. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, analysts anticipate that Alimera Sciences will post ($0.21) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Alimera Sciences, Inc. (ALIM) Given “Buy” Rating at HC Wainwright” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/alimera-sciences-inc-alim-given-a-5-00-price-target-at-hc-wainwright/1533838.html.
A number of institutional investors have recently added to or reduced their stakes in the stock. Kennedy Capital Management Inc. purchased a new position in Alimera Sciences during the first quarter valued at $467,000. KCG Holdings Inc. boosted its stake in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 43,977 shares during the period. JW Asset Management LLC boosted its stake in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after buying an additional 130,000 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 35,200 shares during the period. 37.20% of the stock is owned by hedge funds and other institutional investors.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.